Status: Not yet recruiting
A Study of SHR-1501 Combination With BCG Versus Placebo Combined With BCG in Subjects With Papillary-Only NMIBC
This is a multicenter, randomized, Double-blind phase III study to determine the efficacy and safety of intravesical SHR-1501 combined with Bacillus Calmette Guerin (BCG) versus Placebo Combined with BCG in patients with high-risk BCG-naive Papillary-Only non-muscle-invasive bladder cancer (NMIBC)
Participants needed: 750
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.Updated: Jul 27, 2026Locations: 2
Eligibility criteria
Aged at least 18 years, gender is not limited; [+5]
Previous histopathological diagnosis was muscle-invasive, locally advanced or me... [+6]